Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate

US10806797B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Dieter Kadereit · Kelkheim, DE
• Michael Wagner · Frankfurt am Main, DE
• Thomas Olpp · Frankfurt am Main, DE
• Nino Meyer · Frankfurt am Main, DE
• Pradeep K. Dhal · Westford, US
• Paul A. Konowicz · Farnham, GB
• Robert J. Miller · Halifax, US
• James Stefano · Bound Brook, US
• Magnus Besev · Bound Brook, US
• Martin Bossart · Frankfurt am Main, DE
• Katrin Lorenz · Frankfurt am Main, DE
• Torsten Haack · Frankfurt am Main, DE
• Andreas Evers · Frankfurt am Main, DE

Key dates

• Filing date: Jun 2, 2016
• Grant date: Oct 20, 2020
• Expiry date: Jun 2, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P3/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon agonist linker conjugate Z-L1-L2-L-Y—R20, wherein Y represents an GLP-1/Glucagon agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon agonist.